Regen Therapeutics Limited

Shareholder Update: One Year On From Transferring Colostrinin Rights To Sterling

Shareholder Update June 2019

Post navigation

← Sale of ‘Colostrinin’ Assets to Sterling Technology Inc. Report and Unaudited Financial Statements Year ended 31st December 2019 →
ReGen Therapeutics Limited
  • Home
  • About Us
    • Our History
    • Directors
  • Products & Research
    • Colostrinin as a nutraceutical
    • Pharmaceuticals – Peptides
    • Pharmaceuticals – Zolpidem
    • Presentations
  • News
    • Announcements
    • Events Calendar
    • Email News Alerts
  • Contact Us

Email Alerts

  • Sitemap
  • Links
  • Disclaimer & Cookies
  • Accessibility
  • Contact Us